Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 14/20 | 0.64 |
| ▸ | GRM5 | P41594 | 9/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.64 |
| ▸ | RELA | Q04206 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30132495 | 1.00 | MAOB (0.64) | MAOBGRM5NPC1ALDH1A1HPGD | |
| SCHEMBL7946778 | 0.85 | MAOB (0.64) | MAOBGRM5NPC1ALDH1A1HPGD | |
| SCHEMBL30353218 | 0.78 | MAOB (0.81) | MAOBGRM5NPC1ALDH1A1HPGD | |
| SCHEMBL2326572 | 0.78 | MAOB (1.00) | MAOBGRM5NPC1ALDH1A1HPGD | |
| SCHEMBL6836955 | 0.78 | MAOB (0.81) | MAOBGRM5NPC1ALDH1A1HPGD | |
| SCHEMBL29889798 | 0.78 | MAOB (1.00) | MAOBGRM5NPC1ALDH1A1HPGD | |
| SCHEMBL28454382 | 0.77 | MAOB (0.45) | MAOBGRM5NPC1ALDH1A1HPGD | |
| SCHEMBL22712728 | 0.76 | MAOB (0.62) | MAOBGRM5NPC1ALDH1A1HPGD | |
| SCHEMBL12316589 | 0.76 | MRGPRX4 (0.57) | MAOBGRM5NPC1ALDH1A1HPGD | |
| SCHEMBL13854257 | 0.76 | MAOB (0.59) | MAOBNPC1ALDH1A1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110770211-B | Alpha, beta unsaturated amide compound | 协和麒麟株式会社 | 2023-09-19 | — | — | CN | disclosed |
| CN-108430972-B | Alpha, beta-unsaturated amide compound | 协和麒麟株式会社 | 2022-12-27 | — | — | CN | disclosed |
| US-11447471-B2 | α,β-unsaturated amide compound | KYOWA KIRIN CO., LTD. (JP) | 2022-09-20 | — | — | US | disclosed |
| US-11332455-B2 | α,β-unsaturated amide compound | KYOWA KIRIN CO., LTD. (JP) | 2022-05-17 | — | — | US | disclosed |
| US-20210380551-A1 | ALPHA,BETA-UNSATURATED AMIDE COMPOUND | KYOWA KIRIN CO., LTD. (JP) | 2021-12-09 | — | — | US | disclosed |
| US-20210155612-A1 | Alpha,Beta-UNSATURATED AMIDE COMPOUND | KYOWA KIRIN CO., LTD. (JP) | 2021-05-27 | — | — | US | disclosed |
| US-10787428-B2 | α,β-unsaturated amide compound | KYOWA KIRIN CO., LTD. (JP) | 2020-09-29 | — | — | US | disclosed |
| EP-3712129-A1 | ALPHA, BETA-UNSATURATED AMIDE COMPOUND | Kyowa Kirin Co., Ltd. (JP) | 2020-09-23 | — | — | EP | disclosed |
| CN-110770211-A | α unsaturated amide compound | 协和麒麟株式会社 | 2020-02-07 | — | — | CN | disclosed |
| US-20190010136-A1 | ALPHA,BETA-UNSATURATED AMIDE COMPOUND | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-01-10 | — | — | US | disclosed |
| EP-3401309-A1 | a, ß UNSATURATED AMIDE COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2018-11-14 | — | — | EP | disclosed |
| CN-108430972-A | α, β unsaturated acyl amine compounds | 协和发酵麒麟株式会社 | 2018-08-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155612-A1 | Alpha,Beta-UNSATURATED AMIDE COMPOUND | NR1H2, NR1H3, RXRA | MAOB 3240/4885GRM5 1244/4885NPC1 940/4885 |
| US-11447471-B2 | α,β-unsaturated amide compound | NR1H2, RXRA, RXRB | MAOB 3184/4885GRM5 1075/4885NPC1 1041/4885 |
| US-10787428-B2 | α,β-unsaturated amide compound | NR1H2, NCOA1, NR0B1 | MAOB 3552/4885GRM5 1006/4885NPC1 1218/4885 |
| US-20210380551-A1 | ALPHA,BETA-UNSATURATED AMIDE COMPOUND | NR1H2, NR1H3, NCOA1 | MAOB 3686/4885GRM5 1212/4885NPC1 1039/4885 |
| US-11332455-B2 | α,β-unsaturated amide compound | NR1H2, NCOA1, NR0B1 | MAOB 3552/4885GRM5 1006/4885NPC1 1218/4885 |
| US-20190010136-A1 | ALPHA,BETA-UNSATURATED AMIDE COMPOUND | NR1H2, NR1H3, NCOA1 | MAOB 3686/4885GRM5 1212/4885NPC1 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.